TPX-100: OrthoTrophix Presents New Data Revealing Structural Coupling between Femoral Bone Shape and Meniscal Pathology in Knee Osteoarthritis
Excerpt from the Press Release:
FOSTER CITY, Calif., April 24, 2026 /PRNewswire/ — OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score, and meniscal pathology in patients with knee osteoarthritis (KOA). These findings add to the growing body of evidence supporting the role of bone-shape metrics as reproducible, quantitative structural measures that may reflect disease severity and progression in KOA.
The Company is presenting a late-breaking abstract entitled, “WORMS-Defined Meniscal Pathology is Associated with Femoral Bone-Shape Change, with Attenuation in IA TPX-100 Treated Knees” (Poster #665) at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm Beach, Florida (23 – 26 April 2026). The poster is being presented April 24 – 25.
WORMS (Whole Organ Magnetic Resonance Imaging Score) is a semi-quantitative MRI-based method used to assess structural features of KOA across multiple joint tissues. In this retrospective imaging analysis, femoral bone shape – quantified using the B-score – demonstrated statistically significant associations with WORMS-defined meniscal pathology across timepoints.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?